CAR-T(CAR-T)细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T(CAR-T)细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:Immunometabolic Maladaptations to the Tumor Microenvironment.
Immunometabolic Maladaptations to the Tumor Microenvironment.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
肿瘤由癌细胞以及多种组织驻留和浸润的细胞类型组成。然而,肿瘤代谢研究在很大程度上是在整个肿瘤或癌细胞层面进行的,浸润免疫细胞的代谢仍知之甚少。目前,通过一系列分析和代谢物挽救研究已明确,对肿瘤微环境(TME)的代谢适应会直接阻碍T细胞和巨噬细胞的效应功能。对TME的代谢适应及代谢性免疫抑制的驱动因素包括必需营养物质的耗竭、废物或免疫抑制代谢产物的积累,以及通过改变翻译后修饰进行的代谢信号传导。然而,每种浸润免疫细胞亚群各不相同,具有特定的代谢需求和适应方式,这些适应可能对抗肿瘤免疫不利。在此,我们综述了实体瘤中T细胞和巨噬细胞的适应及代谢性免疫抑制。最终,理解和解决这些挑战将改善癌症免疫治疗和过继性CAR-T 细胞疗法。
Tumors consist of cancer cells and a wide range of tissue resident and infiltrating cell types. Tumor metabolism, however, has largely been studied on whole tumors or cancer cells and the metabolism of infiltrating immune cells remains poorly understood. It is now clear from a range of analyses and metabolite rescue studies that metabolic adaptations to the tumor microenvironment (TME) directly impede T-cell and macrophage effector functions.
The drivers of metabolic adaptation to the TME and metabolic immune suppression include depletion of essential nutrients, accumulation of waste products or immune suppression metabolites, and metabolic signaling through altered posttranslational modifications. Each infiltrating immune cell subset differs, however, with specific metabolic requirements and adaptations that can be maladaptive for antitumor immunity.
Here, we review T-cell and macrophage adaptation and metabolic immune suppression in solid tumors. Ultimately, understanding and addressing these challenges will improve cancer immunotherapy and adoptive chimeric antigen receptor T-cell therapies.
在 PubMed 查看 → 出版商原文(DOI) 全文 PDF(PMC)· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →
MEMBER ACCOUNT
登录成功会直接打开下一页。